Wall Street analysts predict that Clorox Co (NYSE:CLX) will report $1.54 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Clorox’s earnings, with the highest sales estimate coming in at $1.55 billion and the lowest estimate coming in at $1.52 billion. Clorox reported sales of $1.56 billion in the same quarter last year, which indicates a negative year-over-year growth rate of 1.3%. The business is expected to report its next quarterly earnings report on Wednesday, October 30th.

According to Zacks, analysts expect that Clorox will report full-year sales of $6.30 billion for the current fiscal year, with estimates ranging from $6.27 billion to $6.39 billion. For the next year, analysts forecast that the company will report sales of $6.49 billion, with estimates ranging from $6.42 billion to $6.62 billion. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for Clorox.

Clorox (NYSE:CLX) last issued its quarterly earnings data on Thursday, August 1st. The company reported $1.88 earnings per share for the quarter, topping the consensus estimate of $1.84 by $0.04. The company had revenue of $1.63 billion during the quarter, compared to analyst estimates of $1.69 billion. Clorox had a return on equity of 118.88% and a net margin of 13.20%. The firm’s revenue for the quarter was down 3.8% compared to the same quarter last year. During the same period in the prior year, the business posted $1.66 earnings per share.

A number of analysts recently issued reports on CLX shares. Citigroup set a $156.00 price objective on Clorox and gave the stock a “hold” rating in a research report on Thursday, May 23rd. Royal Bank of Canada upped their target price on shares of Clorox to $161.00 and gave the company a “sector perform” rating in a research report on Friday, August 2nd. Wells Fargo & Co reaffirmed a “hold” rating and set a $153.00 target price on shares of Clorox in a research note on Thursday, August 1st. ValuEngine cut shares of Clorox from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Argus downgraded shares of Clorox from a “buy” rating to a “hold” rating in a research note on Monday, May 20th. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and two have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $154.07.

Shares of Clorox stock traded up $0.65 during trading hours on Friday, hitting $158.93. The company’s stock had a trading volume of 826,522 shares, compared to its average volume of 1,004,766. The stock has a market cap of $19.86 billion, a price-to-earnings ratio of 25.15, a P/E/G ratio of 4.99 and a beta of 0.38. The company has a debt-to-equity ratio of 4.09, a quick ratio of 0.55 and a current ratio of 0.91. Clorox has a twelve month low of $141.53 and a twelve month high of $167.70. The firm has a fifty day moving average of $159.87 and a 200-day moving average of $156.21.

In other news, SVP Michael R. Costello sold 6,997 shares of the stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $162.56, for a total transaction of $1,137,432.32. Following the sale, the senior vice president now owns 29,016 shares of the company’s stock, valued at $4,716,840.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director A D. David Mackay sold 3,400 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $154.87, for a total transaction of $526,558.00. The disclosure for this sale can be found here. Insiders have sold a total of 15,609 shares of company stock valued at $2,497,443 over the last 90 days. 1.40% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in CLX. Zions Bancorporation N.A. acquired a new position in shares of Clorox in the first quarter worth $28,000. Northstar Capital Management LLC purchased a new stake in Clorox during the 1st quarter worth about $29,000. Heritage Wealth Advisors purchased a new stake in Clorox during the 2nd quarter worth about $30,000. Penserra Capital Management LLC acquired a new stake in Clorox in the 1st quarter valued at about $36,000. Finally, Trustcore Financial Services LLC acquired a new stake in Clorox in the 1st quarter valued at about $38,000. 78.20% of the stock is currently owned by hedge funds and other institutional investors.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

Further Reading: The Discount Rate – What You Need to Know

Get a free copy of the Zacks research report on Clorox (CLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.